Omega-3 Replacement With Krill Oil in Disease Management of SLE (ORKIDS)
A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)
Sponsor: Aker BioMarine Human Ingredients AS
A NA clinical study on Systemic Lupus Erythematosus (SLE), this trial is completed. The trial is conducted by Aker BioMarine Human Ingredients AS and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Nov 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2021 — Nov 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Recruiting NA
-
Aug 2019 — Aug 2020 [monthly]
Recruiting NA
-
Jan 2019 — Aug 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Jan 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aker BioMarine Human Ingredients AS
- Ampel BioSolutions, LLC
For direct contact, visit the study record on ClinicalTrials.gov .